148 related articles for article (PubMed ID: 37218491)
21. Diabetic Retinopathy as a Risk Factor Associated with the Development of Hepatocellular Carcinoma in Nonalcoholic Fatty Liver Disease.
Azuma S; Asahina Y; Kakinuma S; Azuma K; Miyoshi M; Inoue E; Tsunoda T; Sato A; Kaneko S; Nagata H; Kawai-Kitahata F; Murakawa M; Nitta S; Itsui Y; Tomita M; Nakagawa M; Watanabe M
Dig Dis; 2019; 37(3):247-254. PubMed ID: 30625487
[TBL] [Abstract][Full Text] [Related]
22. Association of nonalcoholic fatty liver disease (NAFLD) with hepatocellular carcinoma (HCC) in the United States from 2004 to 2009.
Younossi ZM; Otgonsuren M; Henry L; Venkatesan C; Mishra A; Erario M; Hunt S
Hepatology; 2015 Dec; 62(6):1723-30. PubMed ID: 26274335
[TBL] [Abstract][Full Text] [Related]
23. Manifold Roles of Ceramide Metabolism in Non-Alcoholic Fatty Liver Disease and Liver Cancer.
Wang K; Wei Y; Xu R; Li Y; Mao C
Adv Exp Med Biol; 2022; 1372():157-168. PubMed ID: 35503180
[TBL] [Abstract][Full Text] [Related]
24. Hepatocellular carcinoma surveillance in patients with non-alcoholic fatty liver disease.
Seif El Dahan K; Daher D; Singal AG
Clin Mol Hepatol; 2023 Feb; 29(Suppl):S207-S219. PubMed ID: 36103899
[TBL] [Abstract][Full Text] [Related]
25. Mechanisms of nonalcoholic fatty liver disease and implications for surgery.
Kaufmann B; Reca A; Wang B; Friess H; Feldstein AE; Hartmann D
Langenbecks Arch Surg; 2021 Feb; 406(1):1-17. PubMed ID: 32833053
[TBL] [Abstract][Full Text] [Related]
26. The role of dietary factors in nonalcoholic fatty liver disease to hepatocellular carcinoma progression: A systematic review.
Zheng J; Zhao L; Dong J; Chen H; Li D; Zhang X; Hassan MM; Steck SE; Li X; Xiang YB; Wang H
Clin Nutr; 2022 Oct; 41(10):2295-2307. PubMed ID: 36096063
[TBL] [Abstract][Full Text] [Related]
27. Predicting Non-Alcoholic Fatty Liver Disease Progression and Immune Deregulations by Specific Gene Expression Patterns.
Zeng F; Zhang Y; Han X; Zeng M; Gao Y; Weng J
Front Immunol; 2020; 11():609900. PubMed ID: 33574818
[TBL] [Abstract][Full Text] [Related]
28. Noninvasive evaluation of nonalcoholic fatty liver disease: Current evidence and practice.
Zhou JH; Cai JJ; She ZG; Li HL
World J Gastroenterol; 2019 Mar; 25(11):1307-1326. PubMed ID: 30918425
[TBL] [Abstract][Full Text] [Related]
29. Fibrosis Severity as a Determinant of Cause-Specific Mortality in Patients With Advanced Nonalcoholic Fatty Liver Disease: A Multi-National Cohort Study.
Vilar-Gomez E; Calzadilla-Bertot L; Wai-Sun Wong V; Castellanos M; Aller-de la Fuente R; Metwally M; Eslam M; Gonzalez-Fabian L; Alvarez-Quiñones Sanz M; Conde-Martin AF; De Boer B; McLeod D; Hung Chan AW; Chalasani N; George J; Adams LA; Romero-Gomez M
Gastroenterology; 2018 Aug; 155(2):443-457.e17. PubMed ID: 29733831
[TBL] [Abstract][Full Text] [Related]
30. NAFLD: Is There Anything New under the Sun?
Lonardo A; Targher G
Int J Mol Sci; 2017 Sep; 18(9):. PubMed ID: 28895919
[TBL] [Abstract][Full Text] [Related]
31. Global publication trends and research hotspots of the gut-liver axis in NAFLD: A bibliometric analysis.
Yang S; Yu D; Liu J; Qiao Y; Gu S; Yang R; Chai X; Wang W
Front Endocrinol (Lausanne); 2023; 14():1121540. PubMed ID: 36967792
[TBL] [Abstract][Full Text] [Related]
32. Clinical relevance of liver histopathology and different histological classifications of NASH in adults.
Nascimbeni F; Ballestri S; Machado MV; Mantovani A; Cortez-Pinto H; Targher G; Lonardo A
Expert Rev Gastroenterol Hepatol; 2018 Apr; 12(4):351-367. PubMed ID: 29224471
[TBL] [Abstract][Full Text] [Related]
33. Models estimating risk of hepatocellular carcinoma in patients with alcohol or NAFLD-related cirrhosis for risk stratification.
Ioannou GN; Green P; Kerr KF; Berry K
J Hepatol; 2019 Sep; 71(3):523-533. PubMed ID: 31145929
[TBL] [Abstract][Full Text] [Related]
34. Non-alcoholic fatty liver disease progresses to hepatocellular carcinoma in the absence of apparent cirrhosis.
Ertle J; Dechêne A; Sowa JP; Penndorf V; Herzer K; Kaiser G; Schlaak JF; Gerken G; Syn WK; Canbay A
Int J Cancer; 2011 May; 128(10):2436-43. PubMed ID: 21128245
[TBL] [Abstract][Full Text] [Related]
35. The Relevance of Noninvasive Tools To Assess Fibrosis in Non-Alcoholic Fatty Liver Disease.
Pennisi G; Celsa C; Giammanco A; Spatola F; Petta S
Curr Pharm Des; 2020; 26(32):3928-3938. PubMed ID: 32436818
[TBL] [Abstract][Full Text] [Related]
36. Hepatic Outcomes of Nonalcoholic Fatty Liver Disease Including Cirrhosis and Hepatocellular Carcinoma.
Alqahtani SA; Chan WK; Yu ML
Clin Liver Dis; 2023 May; 27(2):211-223. PubMed ID: 37024203
[TBL] [Abstract][Full Text] [Related]
37. Positive Hepatitis B Core Antibody Is Associated With Cirrhosis and Hepatocellular Carcinoma in Nonalcoholic Fatty Liver Disease.
Chan TT; Chan WK; Wong GL; Chan AW; Nik Mustapha NR; Chan SL; Chong CC; Mahadeva S; Shu SS; Lai PB; Chan HL; Wong VW
Am J Gastroenterol; 2020 Jun; 115(6):867-875. PubMed ID: 32149781
[TBL] [Abstract][Full Text] [Related]
38. Mild drinking habit is a risk factor for hepatocarcinogenesis in non-alcoholic fatty liver disease with advanced fibrosis.
Kimura T; Tanaka N; Fujimori N; Sugiura A; Yamazaki T; Joshita S; Komatsu M; Umemura T; Matsumoto A; Tanaka E
World J Gastroenterol; 2018 Apr; 24(13):1440-1450. PubMed ID: 29632425
[TBL] [Abstract][Full Text] [Related]
39. Translational approaches: from fatty liver to non-alcoholic steatohepatitis.
Rosso N; Chavez-Tapia NC; Tiribelli C; Bellentani S
World J Gastroenterol; 2014 Jul; 20(27):9038-49. PubMed ID: 25083077
[TBL] [Abstract][Full Text] [Related]
40. New horizon of ultrasound for screening and surveillance of non-alcoholic fatty liver disease spectrum.
Guan X; Chen YC; Xu HX
Eur J Radiol; 2022 Sep; 154():110450. PubMed ID: 35917757
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]